
AZN
AstraZeneca PLC
Company Overview
| Mkt Cap | $314.14B | Price | $189.75 |
| Volume | 2.39M | Change | -1.33% |
| P/E Ratio | 30.7 | Open | $189.15 |
| Revenue | $58.7B | Prev Close | $192.30 |
| Net Income | $10.2B | 52W Range | $132.32 - $212.71 |
| Div Yield | 5.30% | Target | $206.99 |
| Overall | 50 | Value | 50 |
| Quality | 65 | Technical | 36 |
No chart data available
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest News
AstraZeneca Advances New Imaging Tool in Targeted Lung Cancer Trial
Osimertinib Cements Lead in EGFR Lung Cancer as AstraZeneca Updates Key Phase 3 Trial
AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus
AstraZeneca Expands Real‑World Evidence for Acalabrutinib in CLL
AstraZeneca’s Danicopan Korea Study: Real-World Data That Could Shape AZN’s Rare Disease Edge
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AZN | $189.75 | -1.3% | 2.39M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |